About NewVale Capital
NewVale Capital is a venture capital firm founded in 2022. It is primarily based out of Boulder, United States. As of Sep 2025, NewVale Capital is an active investor, having invested in 4 companies, with 1 new investment in the last 12 months. It primarily invests in Series C round in United States based startups. Its investments are spread across a wide range of sectors from Enterprise Applications to HealthTech and Life Sciences. Most recently it participated in the $***** Series C round of Noxilizer NewVale Capital has team of 11 people including 3 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B & Series C
Deals in last 12 months
NewVale Capital's List of All Investments
NewVale Capital has a portfolio of 4 companies. Their most notable investments are in Argonautms and BeaconCure.Their portfolio spans across United States and Israel. They have invested in Enterprise Applications, HealthTech, Life Sciences and 1 other sectors, across stages such as Series B, Series C stages. Here is the list of all investments by NewVale Capital:
1. Aizon
Provider of AI-based software for manufacturing operations. The company provides SAAS solutions for big data analytics and predictive insights. The company offers its solutions to biotech & pharma, cosmetics medical devices, chemicals, nutraceuticals, food & beverage industries. The company offers solutions for performance management, anomaly detection, batch process optimization among others.
Key facts about Aizon
- Founded Year: 2014
- Location: San Francisco (United States)
- Stage: Series C
- Total Funding till date: $44.6M
- Employee Count: 111 as on Jul 01, 2024
- Investors: FCVC, Industry Ventures and 14 Others
- Latest Funding Round: Series C, Feb 07, 2024, $*****
- Highlight: Editors' Pick
2. Noxilizer
Key facts about Noxilizer
- Founded Year: 2004
- Location: Baltimore (United States)
- Stage: Series C
- Total Funding till date: $36.4M
- Employee Count: 32 as on Jul 01, 2024
- Investors: UTEC, NewVale Capital and 1 Other
- Latest Funding Round: Series C, Sep 10, 2025, $*****
3. BeaconCure
Developer of an AI-enabled statistical analysis platform for biometrics teams. The platform unifies review roles within a fit-for-purpose environment. It enhances visible collaboration, accountability, and efficiency. The AI algorithms are refined through metadata extraction and expert feedback. The platform delivers validation, data transformation, and metadata reuse. An automated activity log maintains a real-time audit trail.
Key facts about BeaconCure
- Founded Year: 2016
- Location: Tel Aviv (Israel)
- Stage: Series C
- Total Funding till date: $40.9M
- Employee Count: 35 as on Dec 27, 2025
- Investors: NewVale Capital
- Latest Funding Round: Series C, Jan 03, 2025, $*****
- Highlight: Editors' Pick
4. Argonautms
Contract manufacturing expert for pharma, life sciences, IVD, and drug-device products. They offer comprehensive contract manufacturing services, specializing in aseptic fill & finish, reagent and IVD manufacturing, drug-device combination production, and lyophilization. Their services include formulation, kitting, analytical & quality control, GMP storage & logistics, and regulatory support. They provide flexible and responsive manufacturing solutions, complete supply chain management, and dedicated project leaders for transparency and communication. They focus on quality, innovation, and efficiency to accelerate speed to market with lower risk and less capital expenditures. They work with trusted partners to support needs outside of their capabilities. They aim to improve the human condition by helping partners exceed their goals in the world of health.
Key facts about Argonautms
- Founded Year: 2016
- Location: Carlsbad (United States)
- Stage: Series B
- Total Funding till date: $62.3M
- Employee Count: 116 as on Dec 31, 2022
- Investors: CYwP Funds, Telegraph Hill Partners and 2 Others
- Latest Funding Round: Series B, Mar 05, 2024, $*****
NewVale Capital's Year-on-Year Investment Trends
NewVale Capital has invested in 4 companies over the last 3 years, with an average of 1 new investment annually in the last 3 years. In 2025, it made 1 investment. Its most recent first time investment was in Noxilizer.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 0 | 1 |
2024 | 2 | 0 | 2 |
2023 | 1 | 0 | 1 |
NewVale Capital's Investments by Stage
NewVale Capital has made 2 investments in Series B stage with an average round size of $29.5M and 2 investments in Series C stage with an average round size of $25M.Stage of entry | No. of Investments |
|---|---|
Series B | 2 |
Series C | 2 |
Note: We have considered here, only first round of investments
NewVale Capital's Investments by Sector
NewVale Capital has a diverse portfolio, with companies operating in the Enterprise Applications, HealthTech, Healthcare and Life Sciences. Notably, it has invested in 4 Enterprise (B2B) companies, 2 Saas companies, 2 Software companies and 2 companies focusing on Tech.Sector | No. of Investments |
|---|---|
Enterprise Applications | 2 |
HealthTech | 2 |
Healthcare | 2 |
Life Sciences | 2 |
Note: We have considered here, only first round of investments
NewVale Capital's Investments by Geography
NewVale Capital has made most investments in United States (3), followed by Israel where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 3 |
Israel | 1 |
Note: We have considered here, only first round of investments
NewVale Capital's recent investments
NewVale Capital has not made any investment in 2026 so far.Here are the most recent investments by NewVale Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 10, 2025 | United States | Series C | 7316 | - | |
Mar 05, 2024 | United States | Series B | 8201 | ||
Feb 07, 2024 | United States | Series C | 2438 | [+2] | |
Jun 13, 2023 | Israel | Series B | 6065 | - |
Team profile of NewVale Capital
NewVale Capital has a team of 11 members including 3 Partners and 4 Principals located in United States. NewVale Capital's team does not sit on the board of any company as of now.Here is a list of top team members in NewVale Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Principal | New York City | - | ||
Principal | New York City | - | ||
Principal | - | - | - | |
Principal | - | - | - |
Co-investors of NewVale Capital
Over the past 3 years, 11 investors have co-invested in NewVale Capital's portfolio companies. This includes only funds.
- Invested before NewVale Capital: Crosslink Capital, Uncork Capital and 9 others have invested in rounds before NewVale Capital. There is 1 company where Crosslink Capital has invested before NewVale Capital and 1 company where Uncork Capital has invested before NewVale Capital.
Recent News related to NewVale Capital
•
Noxilizer Secures $30 Million Growth Capital Led by NewVale Capital for NO2 Sterilization Expansionintelligence360•Oct 06, 2025•NewVale Capital, Noxilizer
•
•
NewVale unveils $167M fund to back pharma service providers and 'old ideas that are working'EndPoints News•May 13, 2024•NewVale Capital
•
Argonaut Manufacturing Services Raises $45 MillionPulse 2.0•Mar 06, 2024•Argonautms, NewVale Capital, Telegraph Hill Partners, RBC Capital Markets and 1 other
•
Aizon Secures $20M in Series C Funding Led by NewVale Capital to Enhance Pharma Manufacturing OutcomesBusiness Wire•Feb 08, 2024•Aizon, NewVale Capital, Atlantic Bridge, Crosslink Capital and 2 others
•
Overflow Raises $20M in Series B FundingFinSMEs•Feb 07, 2024•Overflow, Wifonline, Uncork Capital, R7 Partners and 6 others
•
Beaconcure Raises $14 Million Series B to Expand AI-powered Clinical Technology PlatformBusiness Wire•Jun 13, 2023•BeaconCure, NewVale Capital, Pfizer
